Clinical trial

DETECT IV - A Study in Patients With HER2-negative Metastatic Breast Cancer and Persisting HER2-negative Circulating Tumor Cells (CTCs).

NCT02035813

Study summary

ClinicalTrials.gov

DETECT IV - A Study in Patients With HER2-negative Metastatic Breast Cancer and Persisting HER2-negative Circulating Tumor Cells (CTCs).

Design: INTERVENTIONAL · Status: COMPLETED · Phase: PHASE2

Loading study purpose, treatment groups and outcomes…

View the complete registry record, eligibility and contacts at ClinicalTrials.gov

Drugs and interventions used in this trial

2 registered

These interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.

DRUG · Mapped RxNorm record Ribociclib Normalized identity: ribociclib View linked drug · Find medicine records · Find other trials using this name

DRUG · Mapped RxNorm record Eribulin Normalized identity: eribulin View linked drug · Find medicine records · Find other trials using this name

StatusCOMPLETED

Study typeINTERVENTIONAL

Start date2014-01-01

PhasePHASE2

Conditions

HER2-negative and Hormone-receptor Positive Metastatic Breast Cancerunresolved

HER2-negative Circulating Tumor Cellsunresolved

Postmenopausal Female Patientsunresolved

Interventions

RibociclibDRUG · verified · RxNorm: ribociclib

EribulinDRUG · verified · RxNorm: eribulin

Sponsors & collaborators

Prof. Wolfgang Jannilead sponsor

Mapped research locations

UlmBaden-Wurttemberg, Germany1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT02035813 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.